A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
=== Ehrlichman interview === A former Nixon aide suggested that the war on drugs was racially and politically motivated.The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I'm saying? We knew we couldn't make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did. However, because he may have been disillusioned with the Nixon administration following the Watergate scandal, the validity of Ehrlichman's claim has been disputed.
After the ousting of Maduro on 3 January, the United States began increasing its pressure on Mexico to reduce its oil sales to Cuba with President Donald Trump threatening tariffs against any country supplying Cuba with oil. On 9 January, the most recent (as of September 2026) oil shipment from Mexico arrived in Cuba, delivering 85,000 barrels of fuel. Mexico temporarily halted shipments of oil to Cuba by 27 January and Mexican President Claudia Sheinbaum said that the decision to halt oil deliveries was "a sovereign decision". In February 2026, Mexico sent two ships of humanitarian aid to Cuba to help alleviate the impacts of the U.S. embargo.
It was given the name "tocopherol" from the Greek words "τόκος" [tókos, birth], and "φέρειν", [phérein, to bear or carry] meaning in sum "to carry a pregnancy," with the ending "-ol" signifying its status as a chemical alcohol. George M. Calhoun, Professor of Greek at the University of California, was credited with helping with the naming process. Erhard Fernholz elucidated its structure in 1938 and shortly afterward the same year, Paul Karrer and his team first synthesized it. It was known since the 19th century that certain plants contain substances that prevent fat from going rancid. In 1937, it was found that vitamin E was specifically responsible for this. This led to the hypothesis that vitamin E's mechanism of action is as an antioxidant that prevents pathogenic oxidation of lipid and lipoprotein, specifically in biological membranes. Nearly 50 years after the discovery of vitamin E, an editorial in the Journal of the American Medical Association titled "Vitamin in search of a disease" read in part "...research revealed many of the vitamin's secrets, but no certain therapeutic use and no definite deficiency disease in man." The animal discovery experiments had been a requirement for successful pregnancy, but no benefits were observed for women prone to miscarriage. Evidence for vascular health was characterized as unconvincing. The editorial closed with mention of some preliminary human evidence for protection against hemolytic anemia in young children. A role for vitamin E in coronary heart disease was first proposed in 1946 by Evan Shute and colleagues.
The two substrates of this enzyme are 3-nitropropionic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 3-nitroacrylic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-nitropropanoate:NADP+ oxidoreductase.
AlphaFold 1 (2018) was built on work developed by various teams in the 2010s, work that looked at the large databases of related protein sequences now available from many different organisms (most without known 3D structures), to try to find changes at different residues (peptides) that appeared to be correlated, even though the residues were not consecutive in the main chain. Such correlations suggest that the residues may be close to each other physically, even though not close in the sequence, allowing a contact map to be estimated. Building on recent work prior to 2018, AlphaFold 1 extended this by estimating a probability distribution for the distances between residues, effectively transforming the contact map into a distance map. It also used more advanced learning methods than previously to develop the inference. The code was not made publicly available, except to run on sequences of proteins in the 2018 CASP competition.
Sources: en.wikipedia.org
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
There are many physiological mechanisms that control starting and stopping a meal. The control of food intake is a physiologically complex, motivated behavioral system. Hormones such as cholecystokinin, bombesin, neurotensin, anorectin, calcitonin, enterostatin, leptin and corticotropin-releasing hormone have all been shown to suppress food intake. Eating rapidly leads to obesity and overeating, probably because the feelings of satiety can be slower.
== Biology and genetics == S. boulardii was originally described as a species distinct from S. cerevisiae based on phenotypic traits, including the inability to ferment galactose, a reported lack of sporulation under standard laboratory conditions, and increased tolerance to human body temperature, gastric acidity, and digestive enzymes compared with many S. cerevisiae strains. Subsequent molecular and genomic analyses, however, have shown that S. boulardii falls within the genetic diversity of S. cerevisiae, forming a distinct clade most closely related to wine-associated strains. Like other S. cerevisiae strains, S. boulardii possesses 16 nuclear chromosomes and a 2-micron plasmid, and is diploid, carrying genetic determinants for both mating types (MATa and MATα). However, the MATa locus in S. boulardii contains mutations predicted to impair mating and sporulation, which may account for its reduced or absent sporulation phenotype under laboratory conditions. S. boulardii shares with other S. cerevisiae strains the production of secreted proteins reported to interfere with certain bacterial pathogens and their toxins, including a 63-kDa phosphatase (Pho8) that reduces Escherichia coli endotoxin activity and a 54-kDa serine protease (Ysp3) capable of degrading Clostridioides difficile toxins A and B. An additional, as-yet-unidentified protein of approximately 120 kDa has been reported to inhibit cholera toxin–induced increases in intracellular cyclic AMP (cAMP).
Usually, PMR only affects adults over the age of 50. The average age of a person who has PMR is about 70 years old, with the highest prevalence in those older than 70. Women are three times as likely to get PMR as men. People of Western and Northern European descent are more likely to get this disease. It is more likely to affect people of Northern European origin; Scandinavians are especially vulnerable. About 50% of people with temporal arteritis also have polymyalgia rheumatica.
Sources: en.wikipedia.org
== Cost == In Canada, PET scan funding varies by province. In Ontario, as of October 2025, there is no charge to the patient for any PET scans funded as part of the PET Scans Ontario Program. The program funds routine PET services for indications where sufficient evidence exists that the scan benefits the patient and offers advantages over other imaging tests. In the United States, PET scan costs vary significantly by location, facility type, and insurance status. According to Medicare's 2026 payment data, a whole-body PET scan has a national average total cost of $872, with the patient paying approximately $174 after Medicare coverage. In the United Kingdom, the National Health Service provides PET-CT scans free at point of use for eligible patients. In Australia, Medicare subsidies are available for eligible PET services.
== See also == Aponeurosis of the obliquus externus abdominis Aponeurosis of the serratus posterior superior muscle Plantar aponeurosis Inguinal aponeurotic falx Bicipital aponeurosis Palatine aponeurosis Fascia
==== Absorption ==== Pseudoephedrine is orally active and is readily absorbed from the gastrointestinal tract. Its oral bioavailability is approximately 100%. The drug reaches peak concentrations after 1 to 4 hours (mean 1.9 hours) in the case of the immediate-release formulation and after 2 to 6 hours in the case of the extended-release formulation. The onset of action of pseudoephedrine is 30 minutes.
Agouti signalling peptide adopts an inhibitor cystine knot motif. Along with the homologous Agouti-related peptide, these are the only known mammalian proteins to adopt this fold. The peptide consists of 131 amino acids. The lethal yellow mutation (Ay) was the first embryonic mutation to be characterized in mice, as homozygous lethal yellow mice (Ay/ Ay) die early in development, due to an error in trophectoderm differentiation. Lethal yellow homozygotes are rare today, while lethal yellow and viable yellow heterozygotes (Ay/a and Avy/a) remain more common. In wild-type mice agouti is only expressed in the skin during hair growth, but these dominant yellow mutations cause it to be expressed in other tissues as well. This ectopic expression of the agouti gene is associated with the yellow obese syndrome, characterized by early onset obesity, hyperinsulinemia and tumorigenesis.
GCaMP is a genetically encoded calcium indicator (GECI) initially developed in 2001 by Junichi Nakai. It is a synthetic fusion of green fluorescent protein (GFP), calmodulin (CaM), and M13, a peptide sequence from myosin light-chain kinase. When bound to Ca2+, GCaMP fluoresces green with a peak excitation wavelength of 480 nm and a peak emission wavelength of 510 nm. It is used in biological research to measure intracellular Ca2+ levels both in vitro and in vivo using virally transfected or transgenic cell and animal lines. The genetic sequence encoding GCaMP can be inserted under the control of promoters exclusive to certain cell types, allowing for cell-type specific expression of GCaMP. Since Ca2+ is a second messenger that contributes to many cellular mechanisms and signaling pathways, GCaMP allows researchers to quantify the activity of Ca2+-based mechanisms and study the role of Ca2+ ions in biological processes of interest.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。